Revolution Medicines, Inc. Common Stock
Here’s whether Revolution Medicines, Inc. Common Stock (RVMD) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.01% over 10 days); strong 1-year return of +310.6%; 3-month momentum positive (+23.6%); rising volume confirms the move (1.73x 30d avg). Concerns: RSI 89 — overbought, elevated pullback risk. Currently 4.5% off its 52-week high. Score: +6/7.
RVMD is in a confirmed uptrend, trading above both its 50-day ($103.09) and 200-day ($71.19) moving averages. With an RSI of 88.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +310.6% compares to +35.1% for SPY (beat the market by 275.5%).